Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Serum Levels of Autoantibodies and the Risk of Non-Hodgkin Lymphoma and Multiple Myeloma

Principal Investigator
Name
Jonathan Hofmann
Degrees
-
Institution
DCEG - Other
Position Title
-
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2015-0051
Initial CDAS Request Approval
Mar 9, 2015
Title
Serum Levels of Autoantibodies and the Risk of Non-Hodgkin Lymphoma and Multiple Myeloma
Summary
Autoimmune diseases and inflammatory disorders, such as systemic lupus erythematosus and Sjögren’s syndrome, are known to be associated an increased risk of developing non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Recent, large epidemiologic studies have shown that the risks vary by NHL subtype and specific autoimmune disease, providing further insight into the association; however, the biological mechanisms behind this association remain unclear. In order to gain more insight into this association, we propose to examine the relationships between biomarkers of autoimmune disease and the risk of non-Hodgkin lymphoma, including multiple myeloma, in nested case-control study within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Specifically, we plan to measure antinuclear antibodies (ANA), anti-citrullinated protein antibodies (ACPA), and rheumatoid factor as well as specific autoantibodies. Previous retrospective studies have reported that autoantibodies are more common among patients with non-Hodgkin lymphoma, but no prospective studies have evaluated the association to date. In light of the prominent role autoimmune disorders play in lymphomagenesis, the examination of these autoantibodies will expand our understanding of non-Hodgkin lymphoma and multiple myeloma and will yield additional insight into the biological mechanisms underlying this association.
Aims

The objective of the proposed study is to evaluate the association between three autoimmune biomarkers, antinuclear antibodies (ANA), anti-citrullinated protein antibodies (ACPA), and rheumatoid factor, and the risk of non-Hodgkin (NHL) and multiple myeloma (MM) in a prospective study. Secondary aims of the study are to evaluate differences by NHL subtype and to explore associations with nuclear patterns and other specific autoantibodies.

Collaborators

Caroline Besson-Maury (DCEG)
Mark Purdue (Ontario Institute for Cancer Research)
Nathaniel Rothman (DCEG)
Kevin Deane (University of Colorado)
Qing Lan (DCEG)
Sonja Berndt (NCI, DCEG, OEEB)
Jonathan Hofmann (DCEG - Other)

Approved Addenda This project has one or more approved addenda.
  • Serum levels of BAFF and risk of lymphoid malignancies
Related Publications